Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1955 1
1957 1
1958 1
1959 1
1960 1
1962 1
1963 1
1964 1
1965 2
1966 4
1967 4
1968 5
1969 10
1970 3
1971 8
1972 3
1973 4
1974 8
1975 7
1976 8
1977 8
1978 4
1979 10
1980 16
1981 13
1982 9
1983 17
1984 8
1985 21
1986 23
1987 18
1988 8
1989 19
1990 12
1991 21
1992 21
1993 16
1994 28
1995 20
1996 26
1997 33
1998 26
1999 34
2000 39
2001 36
2002 33
2003 49
2004 74
2005 50
2006 50
2007 65
2008 58
2009 54
2010 52
2011 69
2012 81
2013 70
2014 65
2015 84
2016 76
2017 101
2018 103
2019 91
2020 114
2021 135
2022 138
2023 106
2024 116
2025 63

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,200 results

Results by year

Filters applied: . Clear all
Page 1
Engineered CRISPR-Cas9 nuclease with expanded targeting space.
Nishimasu H, Shi X, Ishiguro S, Gao L, Hirano S, Okazaki S, Noda T, Abudayyeh OO, Gootenberg JS, Mori H, Oura S, Holmes B, Tanaka M, Seki M, Hirano H, Aburatani H, Ishitani R, Ikawa M, Yachie N, Zhang F, Nureki O. Nishimasu H, et al. Among authors: hirano s. Science. 2018 Sep 21;361(6408):1259-1262. doi: 10.1126/science.aas9129. Epub 2018 Aug 30. Science. 2018. PMID: 30166441 Free PMC article.
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Uesaka K, et al. Among authors: hirano s. Lancet. 2016 Jul 16;388(10041):248-57. doi: 10.1016/S0140-6736(16)30583-9. Epub 2016 Jun 2. Lancet. 2016. PMID: 27265347 Clinical Trial.
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T, Nakagawa H. Wardell CP, et al. Among authors: hirano s. J Hepatol. 2018 May;68(5):959-969. doi: 10.1016/j.jhep.2018.01.009. Epub 2018 Jan 31. J Hepatol. 2018. PMID: 29360550 Free article.
Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers.
Mueller M, Breuer E, Mizuno T, Bartsch F, Ratti F, Benzing C, Ammar-Khodja N, Sugiura T, Takayashiki T, Hessheimer A, Kim HS, Ruzzenente A, Ahn KS, Wong T, Bednarsch J, D'Silva M, Koerkamp BG, Jeddou H, López-López V, de Ponthaud C, Yonkus JA, Ismail W, Nooijen LE, Hidalgo-Salinas C, Kontis E, Wagner KC, Gunasekaran G, Higuchi R, Gleisner A, Shwaartz C, Sapisochin G, Schulick RD, Yamamoto M, Noji T, Hirano S, Schwartz M, Oldhafer KJ, Prachalias A, Fusai GK, Erdmann JI, Line PD, Smoot RL, Soubrane O, Robles-Campos R, Boudjema K, Polak WG, Han HS, Neumann UP, Lo CM, Kang KJ, Guglielmi A, Park JS, Fondevila C, Ohtsuka M, Uesaka K, Adam R, Pratschke J, Aldrighetti L, De Oliveira ML, Gores GJ, Lang H, Nagino M, Clavien PA. Mueller M, et al. Among authors: hirano s. Ann Surg. 2021 Nov 1;274(5):780-788. doi: 10.1097/SLA.0000000000005103. Ann Surg. 2021. PMID: 34334638
Artery-first approach for pancreaticoduodenectomy.
Kawai M, Hirano S, Yamaue H. Kawai M, et al. Among authors: hirano s. J Hepatobiliary Pancreat Sci. 2018 Jun;25(6):319-320. doi: 10.1002/jhbp.554. J Hepatobiliary Pancreat Sci. 2018. PMID: 29665296 No abstract available.
PAM-flexible Engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics.
Acharya S, Ansari AH, Kumar Das P, Hirano S, Aich M, Rauthan R, Mahato S, Maddileti S, Sarkar S, Kumar M, Phutela R, Gulati S, Rahman A, Goel A, Afzal C, Paul D, Agrawal T, Pulimamidi VK, Jalali S, Nishimasu H, Mariappan I, Nureki O, Maiti S, Chakraborty D. Acharya S, et al. Among authors: hirano s. Nat Commun. 2024 Jun 28;15(1):5471. doi: 10.1038/s41467-024-49233-w. Nat Commun. 2024. PMID: 38942756 Free PMC article.
General surgery education across three continents.
McIlhenny C, Kurashima Y, Chan C, Hirano S, Domínguez-Rosado I, Stefanidis D. McIlhenny C, et al. Among authors: hirano s. Am J Surg. 2018 Feb;215(2):209-213. doi: 10.1016/j.amjsurg.2017.12.002. Epub 2017 Dec 5. Am J Surg. 2018. PMID: 29246406 Review.
TRIM22 negatively regulates MHC-II expression.
Inoue A, Watanabe M, Kondo T, Hirano S, Hatakeyama S. Inoue A, et al. Among authors: hirano s. Biochim Biophys Acta Mol Cell Res. 2022 Oct;1869(10):119318. doi: 10.1016/j.bbamcr.2022.119318. Epub 2022 Jun 28. Biochim Biophys Acta Mol Cell Res. 2022. PMID: 35777501 Free article.
2,200 results